Hair Relaxer Trial Settlement: L'Oréal and Co-Defendants Settle First Cancer Trial in Chicago
The first hair relaxer trial settlement came on November 16, a week into a Cook County trial: L'Oréal USA and other makers resolved four women's cancer claims for a confidential sum. No verdict, no fund, and 12,743 federal MDL cases are untouched.
Torts Desk··16 min read

The first hair relaxer trial settlement in the United States was reached on Monday, November 16, 2026, when L'Oréal USA and the other manufacturers on trial in the Circuit Court of Cook County, Illinois, settled the cancer claims of four women a week after jury selection began. The amount is confidential, no jury heard a verdict, and the deal resolves only those four state-court cases, leaving the 12,743 actions pending in the federal hair relaxer litigation, MDL No. 3060, on their existing track toward a first bellwether trial in September 2027.
That is the whole of the public record so far, and it is thinner than the headlines suggest. The settlement does not create a fund, a matrix or a claims process; nobody outside the four plaintiffs can join it. But the timing carries information. A defendant group that had spent three years preparing for the first jury test of the claim that chemical straighteners cause uterine and ovarian cancer chose to pay rather than let a Chicago jury deliberate, and it did so four days after the federal judge in the same city admitted most of the plaintiffs' general causation experts. This article sets out what is known, what is not, and what the hair relaxer trial settlement means for the thousands of claims that remain.
Did L'Oréal settle the hair relaxer lawsuit?
Yes, but only four cases. L'Oréal USA, the U.S. subsidiary of L'Oréal SA, and the other defendants in the first hair relaxer trial settled with four plaintiffs on November 16, 2026, according to the women's attorneys as reported by Reuters. Counsel for the women told Allure that all defendants in the case settled.
The trial was in state court, not the federal MDL. The four women sued L'Oréal's U.S. unit and several other makers of chemical straightening products in Cook County in 2023 and 2024, and their claims were tried together. The Chicago plaintiffs' firm Coplan + Crane described the proceeding before trial as the nation's first multi-plaintiff hair relaxer trial, with its partner Ben Crane serving as co-counsel and leading jury selection, which started on November 9.
What has not been resolved is everything else: the federal MDL, the other state-court dockets in Illinois and Georgia, and the consumer protection suits brought by the Arizona and Minnesota attorneys general. L'Oréal has not admitted liability. A spokesperson told reporters that the company's highest priority is the health and wellbeing of its consumers, that it strictly follows all regulations in every market where it operates, and that it remains confident in the safety of its SoftSheen-Carson brand products, which include relaxers. The company's long-standing position is that the National Institutes of Health study behind the litigation did not establish a causal link between the products and the conditions plaintiffs allege.
What happened in the first hair relaxer trial?
The first hair relaxer trial lasted about a week, from jury selection on November 9 to settlement on November 16, and ended before any verdict. Public reporting does not say whether opening statements had been delivered or whether any witness had testified, and it does not name the presiding judge. Plaintiff-side trackers have reported that consolidated hair relaxer cases in Cook County are managed on a single docket, but the trial judge for this group has not been confirmed in coverage of the settlement.
The sequence, as far as it can be pinned down from the reporting:
| Date | Event | Source |
|---|---|---|
| Oct. 17, 2022 | NIH announces Sister Study findings associating frequent straightener use with higher uterine cancer risk | NIH |
| 2023–2024 | Lindsey, Jenkins, Lofton and Simpson file in the Circuit Court of Cook County | Reuters |
| Feb. 6, 2023 | JPML centralizes federal cases as MDL No. 3060 in the Northern District of Illinois | JPML |
| Oct. 22, 2026 | Federal court admits plaintiffs' lead epidemiologist, limits toxicologist | Mealey's; Consumer Notice |
| Nov. 9, 2026 | Jury selection begins in Cook County | Reuters; Coplan + Crane |
| Nov. 12, 2026 | Federal court admits four more general causation experts, excludes two | Mealey's |
| Nov. 16, 2026 | All defendants settle with the four plaintiffs; terms confidential | Reuters; Allure |
| Sept. 2027 | First federal bellwether trial scheduled in MDL No. 3060 | Docket entry, as reported |
The defendants' identities beyond L'Oréal USA have not been reported in coverage of the settlement. In the federal MDL, the lead defendants include L'Oréal USA, Revlon and Strength of Nature, alongside a later-added group of "Second Wave" manufacturers, but which of those companies were parties to the four Cook County cases is not public. Global Cosmetics News reported that several other hair care manufacturers also reached settlements in the Cook County case, which is consistent with counsel's statement that every defendant settled.
Who were the plaintiffs in the first hair relaxer trial?
The plaintiffs in the first hair relaxer trial were MaryAnne Lindsey, Surenthia Jenkins, Miranda Lofton and Sandra Simpson, four women who allege that years of using chemical hair straighteners caused their gynecologic cancers. Their trial counsel included Danielle Ward Mason, who told Reuters she hoped the settlement would give the women a sense of justice.
Mason's statement to Allure was sharper. She said the women had trusted the defendants' assurances that the products were safe and "have paid a heavy price for that trust," and added that "our work is far from over," a signal that the trial team has other hair relaxer clients in the pipeline. Coverage has not broken down which cancer each woman was diagnosed with or which products each used. Those are the facts that would have mattered most to a jury, because Product Identification and exposure history decide Specific Causation in each case even when General Causation has been accepted.
The multi-plaintiff format is itself notable. Trying four plaintiffs together lets the plaintiffs present a single body of corporate-conduct and scientific evidence once, and it lets a jury see the alleged harm as a pattern rather than an outlier. Defendants generally resist consolidated personal injury trials for that reason, arguing that jurors who hear several injured plaintiffs at once are more likely to attribute harm to the product and less likely to weigh each plaintiff's alternative risk factors separately. Whatever the court's reasons for trying the four together, the format raised the stakes of a loss for the defense: a single adverse verdict form would have carried four damages awards.
How much was the L'Oréal hair relaxer settlement?
The amount of the L'Oréal hair relaxer settlement has not been disclosed. The women's lawyers told Reuters the cases settled for a confidential sum, and neither L'Oréal nor any other defendant has stated a figure. Because the plaintiffs are adults settling their own claims, Illinois law does not require court approval of the terms, so no public filing is likely to reveal the number.
Two cautions follow for anyone trying to value hair relaxer claims from this event. First, a confidential settlement of four hand-picked trial cases is not a benchmark. Trial cases are typically chosen because they are strong, and the price of avoiding a verdict includes the defendants' assessment of how a public loss would affect thousands of other claims, a premium that ordinary inventory cases do not command. Second, figures circulating on claimant-intake websites that purport to estimate per-case hair relaxer settlement values are not derived from this deal. No verifiable hair relaxer settlement amount exists in the public record as of November 18, 2026.
Why did L'Oréal settle the hair relaxer trial?
The defendants have not explained the decision, and any account of their reasons is inference. But the record points to several pressures that made settling the first hair relaxer trial rational even for companies that dispute causation.
The federal causation record had just turned against them. Four days before the Cook County deal, on November 12, U.S. District Judge Mary M. Rowland ruled on six more of the plaintiffs' general causation experts in MDL No. 3060, admitting four and excluding two. Combined with her October 22 ruling admitting the plaintiffs' epidemiologist, Dr. Cote, and admitting toxicologist Mr. Atwood in part, the federal court had cleared six of ten challenged experts under amended Federal Rule of Evidence 702. A state court is not bound by those rulings; Illinois applies its own expert-admissibility standard. But the federal rulings removed the defense argument that the science is too weak for any court to let a jury hear it, and a Cook County judge weighing the same experts would know that a federal judge applying the stricter federal rule had largely admitted them.
Illinois damages law offers defendants little protection. Illinois has no enforceable statutory cap on compensatory damages in personal injury cases. The Illinois Supreme Court struck down the legislature's 1995 cap on noneconomic damages in Best v. Taylor Machine Works (1997) and the medical malpractice cap in Lebron v. Gottlieb Memorial Hospital (2010). Since July 1, 2021, 735 ILCS 5/2-1303(c) has added prejudgment interest of 6% a year on personal injury and wrongful death damages, other than Punitive Damages, sanctions and statutory fees and costs, running from the date the case was filed for up to five years and reduced by qualifying settlement offers. For complaints filed in 2023 and 2024, a verdict in late 2026 would have carried roughly two to three years of interest on top of the award.
Several liability is a limited shield. Under 735 ILCS 5/2-1117, a defendant found less than 25% at fault is only severally liable for damages other than medical expenses, but a defendant at 25% or more is jointly and severally liable for the whole award. In a trial against multiple manufacturers, a defendant whose products a plaintiff used most heavily faced exposure to every dollar the jury awarded, not just its share.
Punitive damages were a live risk. Illinois requires a plaintiff in a product liability case to obtain leave of court before pleading punitive damages, under 735 ILCS 5/2-604.1, after showing a reasonable likelihood of proving facts sufficient to support an award. Whether the Cook County plaintiffs had obtained that leave has not been reported. The plaintiffs' theory, echoed in the Arizona and Minnesota attorney general complaints, is that manufacturers knew or should have known of a cancer risk and marketed the products to Black women and girls without warning; that is the kind of evidence on which punitive claims are built.
A first verdict sets the market. The most important pressure is the simplest. In any Mass Tort, the first verdict anchors settlement values for every case behind it. A large plaintiffs' verdict in Chicago would have repriced more than 12,700 federal cases and the state dockets overnight, and it would have arrived ten months before the federal bellwether calendar starts. A defense verdict would have helped, but not as much as a loss would have hurt. Confidential settlement removes both tails and leaves the first public jury test to the federal Bellwether Trial in 2027.
Does the hair relaxer trial settlement affect the federal MDL?
Not directly. The hair relaxer trial settlement resolves four Cook County cases and has no legal effect on MDL No. 3060, In re Hair Relaxer Marketing, Sales Practices, and Products Liability Litigation, pending before Judge Rowland in the Northern District of Illinois. It does not stay or change any federal deadline, does not bind any federal plaintiff, and does not create a Global Settlement or a Qualified Settlement Fund (QSF).
Its practical effect is a different matter. Settlement negotiators on both sides now know that the defendants were prepared to pay to avoid a verdict on these facts, in this forum, at this point in the science. That is not a concession of causation, and L'Oréal has been explicit that it concedes none. But it is a data point that will be used in every mediation that follows.
The two tracks compared:
| Cook County (state) | MDL No. 3060 (federal) | |
|---|---|---|
| Court | Circuit Court of Cook County, Illinois | U.S. District Court, N.D. Illinois (Rowland, J.) |
| Cases | Consolidated state docket; four tried and settled | 12,743 pending of 17,018 filed (JPML, Nov. 2, 2026) |
| Expert standard | Illinois evidence law | Federal Rule of Evidence 702 (amended 2023) |
| Causation rulings | None reported before settlement | Six of ten challenged experts admitted in whole or part; two excluded; two pending |
| Trial status | First multi-plaintiff trial settled Nov. 16, 2026 | First bellwether set for Sept. 2027 |
| Settlement vehicle | Individual confidential settlements | None; no global deal announced |
| Common benefit assessment | Outside MDL orders unless a participation agreement provides otherwise | MDL Common Benefit Fund assessment applies to federal recoveries |
When is the next hair relaxer trial?
The next confirmed hair relaxer trial date is the first federal bellwether in MDL No. 3060, set for September 2027 in Chicago. A September 24, 2026 docket notification set the start for Tuesday, September 7, 2027; some reports, including Consumer Notice and HarrisMartin, give September 9, 2027 and describe the first bellwether as a case against L'Oréal USA. The docket entry controls.
Before that, the federal schedule as reported runs:
- December 21, 2026: close of expert discovery in the five bellwether cases.
- January 11, 2027: summary judgment and case-specific Rule 702 motions, with oppositions on February 10 and replies on February 24.
- January–August 2027: monthly case management conferences.
- July 15, 2027: close of discovery for the Second Wave defendants under Case Management Order No. 24.
Additional state-court settings in Cook County and in Georgia have been reported by plaintiff-side sources, but none has been confirmed in court records available at the time of writing, and the November 16 settlement may itself reshuffle the Cook County sequence. Counsel with state inventory should work from the operative case management order rather than tracker dates.
How many hair relaxer lawsuits are pending?
The JPML's November 2, 2026 report lists 12,743 pending actions in MDL No. 3060, out of 17,018 filed since centralization on February 6, 2023. That makes the hair relaxer docket one of the four largest MDLs in the federal courts by pending actions. Additional cases sit in state court in Illinois and Georgia; no public figure aggregates them.
In Georgia, the state-court docket is shaped by Burroughs v. Strength of Nature Global, LLC, in which the Supreme Court of Georgia held in 2025 that the ten-year Statute of Repose for product liability claims runs from each retail sale, not from the product's first sale. Claimants who used relaxers within ten years of filing can therefore proceed on at least some purchases. Illinois and federal plaintiffs face their own Statute of Limitations questions, which typically turn on the Discovery Rule and when a plaintiff knew or should have known that her cancer might be connected to relaxer use; the October 2022 NIH announcement is the date defendants most often argue started the clock.
What did the NIH study find about hair relaxers and cancer?
The litigation rests on the NIH's Sister Study, announced October 17, 2022, which followed 33,497 U.S. women for nearly 11 years and recorded 378 uterine cancer diagnoses. Women who reported using hair straightening products more than four times in the previous year were more than twice as likely to develop uterine cancer as women who never used them. The study's lead author estimated that 1.64% of never-users would develop uterine cancer by age 70, compared with 4.05% of frequent users.
The study's limits are the defendants' main argument. It reports an association, not causation, and it did not collect data on the brands or ingredients of the products women used. Plaintiffs answer that the federal court has now accepted, at least at the general causation stage, that experts may evaluate relaxers as finished products, a mixture of constituents, without identifying a single culpable chemical, provided each step of their analysis is reliable. That ruling is federal, but it frames the same science any state court will see.
The state attorney general cases against L'Oréal
Two states are suing L'Oréal over relaxer marketing, and neither case depends on proving that relaxers caused any particular woman's cancer.
- Arizona. Attorney General Kris Mayes filed a consumer fraud action against L'Oréal USA and SoftSheen-Carson in Maricopa County Superior Court in September 2026, the first state to sue over alleged cancer risks from relaxers.
- Minnesota. Attorney General Keith Ellison sued L'Oréal on October 23, 2026 under the Minnesota Prevention of Consumer Fraud Act, the Uniform Deceptive Trade Practices Act and the False Statement in Advertising Act, alleging the company failed to disclose research linking frequent relaxer use to uterine and ovarian cancer and marketed the products to Black women and girls.
These suits seek civil penalties, restitution and injunctive relief, not personal injury compensation. They matter to the private litigation in two ways: discovery taken by a state may surface internal documents that private plaintiffs will seek, and an injunction requiring new warnings would sharpen the failure-to-warn theory for earlier sales. The Cook County settlement has no effect on either.
What the hair relaxer trial settlement means for plaintiffs' firms, defendants and funders
For plaintiffs' firms with Cook County inventory. The settlement shows that the state docket can produce trial-date pressure ahead of the federal calendar, which is the classic reason to file in state court. Firms with trial-ready Illinois cases have a concrete precedent for a pre-verdict resolution, but not a price. Because the terms are confidential, firms that were not part of the trial team have no number to cite to clients, and should be careful not to imply one.
For firms with federal MDL cases. Nothing changes procedurally. Plaintiff Fact Sheet (PFS) compliance, product use records and pathology remain what separates a case that can be valued from one that will be dismissed; the federal court has already dismissed noncompliant cases, some with prejudice. The January 2027 case-specific Rule 702 motions in the bellwether pool are the next events that will move federal values.
For defendants. The settlement buys ten months without a public verdict, but it also removes the chance of an early defense win that could have reset expectations. Defendants now go into the federal bellwethers with a record in which the federal court has admitted most of the plaintiffs' general causation experts and the defense has settled the first trial it faced. Expect continued pressure on specific causation, product identification and timeliness as the main defense levers, and expect a sustained effort to keep the next state-court trials from reaching a jury before September 2027.
For litigation funders and lenders. Third-Party Litigation Funding in hair relaxer portfolios has been priced on the assumption of a long road to a first verdict. A confidential mid-trial settlement validates the claim that the litigation has settlement value but does not supply a valuation input, and it does not shorten the federal timetable. Funders with exposure to state inventory may see faster liquidity events; funders concentrated in the MDL should not.
For claimants. There is no hair relaxer class action settlement to join and no claims deadline arising from this deal. A woman diagnosed with uterine, ovarian or another gynecologic cancer after long-term relaxer use who has not filed a claim faces limitation and repose deadlines that depend on her state and her facts, not on this settlement.
FAQ
Is there a hair relaxer class action settlement I can join?
No. The November 16, 2026 hair relaxer trial settlement covers only the four Cook County plaintiffs. No class action settlement, global settlement or claims fund exists for hair relaxer cancer claims, and the federal MDL is a collection of individual personal injury cases, not a Class Action.
Did L'Oréal admit that hair relaxers cause cancer?
No. L'Oréal said it remains confident in the safety of its SoftSheen-Carson products and has maintained that the NIH study did not establish a causal link. A settlement before verdict is not an admission of liability, and no court or jury has found that relaxers caused any plaintiff's cancer.
Who settled in the first hair relaxer trial?
L'Oréal USA and every other defendant in the four Cook County cases settled, according to plaintiffs' counsel. The other defendants have not been named in coverage of the settlement.
Does the settlement change the value of other hair relaxer cases?
Not formally. The terms are confidential, so the deal provides no public benchmark, and it binds no other case. Informally, it tells both sides that the defense preferred to pay rather than risk the first jury verdict, which will feature in later negotiations.
Which cancers are alleged in hair relaxer lawsuits?
Most hair relaxer lawsuits allege uterine cancer, including endometrial cancer, and ovarian cancer; the four Cook County plaintiffs alleged gynecologic cancers. The federal bellwether pool includes one ovarian cancer case, and the Minnesota attorney general's complaint cites research on further cancer types.
When will the hair relaxer MDL settle?
No date has been announced and no global settlement is reported to be under negotiation in public filings. The next scheduled events that could move settlement are the January 2027 bellwether summary judgment and Rule 702 motions and the first federal trial in September 2027.
Published for legal professionals. Analysis and summaries only — not legal advice, and no attorney-client relationship is created by use of this site.
Read next

Hair Relaxer Lawsuit Update: Judge Admits Four More Cancer Experts, Excludes Two in MDL 3060
In the latest hair relaxer lawsuit update, Judge Mary Rowland ruled on November 12 on six more plaintiffs' general causation experts, admitting four and excluding two. Eight of the ten challenged experts are now decided, and the 12,743-case MDL keeps its 2027 trial path.
Torts Desk · 23 min

Hair Relaxer Bellwether Trial Date Set: First MDL 3060 Trial Starts September 7, 2027
A 24 September 2026 docket entry fixed the hair relaxer bellwether trial date at 7 September 2027 and set eight monthly conferences before it. The case has not been picked, the Rule 702 general causation motion is still undecided, and 12,129 federal claims wait on the result.
Torts Desk · 23 min

L'Oréal Talc Liabilities: Weil and Ducera Hired to Explore Selling US Claims Outside Bankruptcy
L'Oréal's US unit has retained Weil Gotshal and Ducera Partners to explore moving its US talc liabilities into a separate entity and selling it, a Honeywell-style exit that avoids Chapter 11. Talc-asbestos suits rose from about 620 to 760 in six months.
Torts Desk · 15 min